Evaluation of a New Screening Method for Sarcopenia in Rheumatoid Arthritis
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- CHU de Reims
- Enrollment
- 164
- Locations
- 1
- Primary Endpoint
- Quadricepsmeasurement
Study Overview
Brief Summary
Evaluation of a new screening method for sarcopenia in rheumatoid arthritis
Detailed Description
Rheumatoid arthritis (RA) is the most common inflammatory rheumatic disease, affecting 0.4-0.8% of the population. This inflammatory rheumatism leads to progressive, bilateral and symmetrical joint destruction, predominantly in the hands, which is responsible for significant functional repercussions, a sedentary lifestyle and a reduction in physical capacities leading to the onset of comorbidities. Among these comorbidities, sarcopenia is an emerging concept.
Sarcopenia is defined as a decrease in the quality and quantity of a person's muscles. It can be primary, and therefore due to physiological ageing, or secondary to a chronic disease such as inflammatory rheumatism. The definition of sarcopenia has become consensual since the 2019 European Working group on Sarcopenia in Older People (EWGSOP) recommendations and is characterised by:
- A decrease in strength. It is assessed by the grip test with a threshold of 27 kg in men and 16 kg in women. When this manual grip measurement is not possible, the authors advise measurement on an isokinetic device.
- a decrease in overall muscle mass. This is assessed either by dual energy X-ray absorptiometry (DEXA whole body, the reference technique) and defined by a decrease in the appendicular muscle mass index (AMMI) < 7 kg/m² in men and < 5.5 kg/m² in women (AMMI corresponds to the lean mass of the 4 limbs in relation to the height for Europeans); or on the scanographic measurement of the surface of the psoas muscle at L3.
- a decrease in muscular performance. This last point makes it possible to evaluate the severity of this sarcopenia. Muscular performance is assessed by walking speed and/or tests combining balance and walking such as the short physical performance battery test (SPPB) or the timed up and go (TUG).
The diagnosis of sarcopenia is certain when there is a decrease in muscle mass; it is characterised as severe when there is a decrease in physical performance.
Two other concepts are associated:
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Rheumatoid arthritis defined according to ACR/EULAR 2010 criteria,
- •Follow-up at the University Hospital of Reims,
- •Signed consent
Exclusion Criteria
- •Inability to perform a functional test (walking test)
- •Patient under legal protection
- •Patients not affiliated to the social security system
- •Pregnant women
Arms & Interventions
Sarcopenia
Only one arm with the sarcopenia assessment.
Intervention: Microfet2® (Device)
Outcomes
Primary Outcomes
Quadricepsmeasurement
Time Frame: Day 0
The three measurements will be performed by two different operators and the results will be expressed in Newton/m.
Secondary Outcomes
No secondary outcomes reported